Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects

BACKGROUND AND OBJECTIVE: Azilsartan medoxomil (AZL-M) is an angiotensin II receptor blocker approved to treat hypertension. After oral dosing, AZL-M is quickly hydrolyzed to azilsartan (AZL). The aims of this study were to assess the effects of age, sex, and race on the pharmacokinetics of AZL-M in...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrell, Robert E., Karim, Aziz, Zhang, Wencan, Dudkowski, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823318/
https://www.ncbi.nlm.nih.gov/pubmed/26507722
http://dx.doi.org/10.1007/s40262-015-0333-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823318/
https://www.ncbi.nlm.nih.gov/pubmed/26507722
http://dx.doi.org/10.1007/s40262-015-0333-8

Ejemplares similares